Last 33 quarters of trend data · Healthcare · Immunology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -44.92 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 9.25 | 4.98 | 5.37 | 5.56 | 3.50 | 1.74 | 1.38 | 1.17 | 0.85 | 1.07 | 20.47 | 8.72 | 7.94 | 0.69 | 0.61 | 0.75 | 0.82 | 0.68 | 0.82 | 0.53 | 1.15 |
| — | +186.1% | +289.7% | +374.2% | +310.4% | +62.0% | -93.3% | -86.6% | -89.3% | +55.5% | +3272.3% | +1057.0% | +866.8% | +1.0% | -26.3% | +42.3% | -28.7% | -3.0% | -31.2% | -42.8% | +14.5% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 15.43 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.7% | -4.3% | -5.1% | -6.6% | -6.2% | -7.3% | -6.9% | -5.6% | -9.2% | -15.3% | -65.7% | -5.6% | -2.6% | -6.6% | -10.5% | -8.0% | -7.6% | -7.3% | -10.6% | -6.6% | -15.7% |
| — | +40.7% | +25.8% | -18.1% | +33.0% | +52.2% | +89.4% | -1.0% | -259.5% | -130.9% | -523.1% | +30.4% | +66.3% | +9.4% | +0.2% | -22.1% | +51.5% | +61.6% | +29.3% | +49.0% | +9.9% | |
| ROA | -23.8% | -4.2% | -5.0% | -6.4% | -5.9% | -7.0% | -6.7% | -5.4% | -8.2% | -12.8% | -63.1% | -5.4% | -2.5% | -6.2% | -9.9% | -7.5% | -7.2% | -6.9% | -10.0% | -6.3% | -13.6% |
| — | +39.7% | +25.1% | -18.0% | +28.1% | +45.3% | +89.4% | -0.8% | -236.4% | -106.9% | -539.4% | +28.2% | +65.9% | +9.9% | +1.5% | -19.9% | +47.3% | +58.5% | +24.5% | +44.9% | +9.8% | |
| ROIC | -24.5% | -5.0% | -5.8% | -6.3% | -6.3% | -7.5% | -7.6% | -6.2% | -22.6% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +33.5% | +23.0% | -1.3% | +72.3% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | — | 0.00 |
| — | -37.7% | -66.3% | +43.0% | +61.6% | +36.1% | +818.5% | +89.9% | -66.5% | -69.9% | -92.2% | -84.7% | -11.3% | +40.5% | -2.2% | — | +251.5% | -13.9% | +194.5% | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | 0.01 | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 22.37 | 29.62 | 38.51 | 23.76 | 22.37 | 16.94 | 27.42 | 30.03 | 28.89 | 22.89 | 26.61 | 23.19 | 59.01 | 18.59 | 15.56 | 18.75 | 17.54 | 23.86 | 14.28 | 34.01 | 8.71 |
| — | +74.9% | +40.5% | -20.9% | -22.6% | -26.0% | +3.0% | +29.5% | -51.0% | +23.2% | +71.0% | +23.7% | +236.5% | -22.1% | +8.9% | -44.9% | +101.2% | +273.6% | +55.9% | +294.9% | +1.2% | |
| Quick Ratio | 22.37 | 29.62 | 38.51 | 23.76 | 22.37 | 16.94 | 27.42 | 30.03 | 28.89 | 22.89 | 26.61 | 23.19 | 59.01 | 18.59 | 15.56 | 18.75 | 17.54 | 23.86 | 14.28 | 34.01 | 8.71 |
| — | +74.9% | +40.5% | -20.9% | -22.6% | -26.0% | +3.0% | +29.5% | -51.0% | +23.2% | +71.0% | +23.7% | +236.5% | -22.1% | +8.9% | -44.9% | +101.2% | +273.6% | +55.9% | +294.9% | +1.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | -55.79 | — | — | — | — | — | — | — | — | — | -994.50 | -436.00 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 33 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ORKA stock.
Oruka Therapeutics, Inc.'s current P/E is -44.9x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Oruka Therapeutics, Inc.'s business trajectory between earnings reports.